(-0.70%) 5 036.30 points
(-1.07%) 38 050 points
(-0.99%) 15 558 points
(0.06%) $82.86
(-1.88%) $1.622
(0.14%) $2 341.60
(0.05%) $27.36
(0.74%) $922.60
(-0.33%) $0.931
(-0.16%) $10.97
(-0.45%) $0.799
(-0.06%) $92.27
Live Chart Being Loaded With Signals
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally...
Stats | |
---|---|
Today's Volume | 67.81M |
Average Volume | 38.65M |
Market Cap | 77.38B |
EPS | HKD0 ( 2024-03-19 ) |
Next earnings date | ( HKD0.150 ) 2024-05-22 |
Last Dividend | HKD0.140 ( 2023-09-07 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 12.30 |
ATR14 | HKD0.0110 (0.17%) |
Volume Correlation
CSPC Pharmaceutical Group Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
CSPC Pharmaceutical Group Correlation - Currency/Commodity
CSPC Pharmaceutical Group Financials
Annual | 2023 |
Revenue: | HKD34.75B |
Gross Profit: | HKD24.51B (70.51 %) |
EPS: | HKD0.550 |
Q4 | 2023 |
Revenue: | HKD16.60B |
Gross Profit: | HKD11.82B (71.17 %) |
EPS: | HKD0.260 |
Q3 | 2023 |
Revenue: | HKD7.78B |
Gross Profit: | HKD5.55B (71.35 %) |
EPS: | HKD0 |
Q2 | 2023 |
Revenue: | HKD8.03B |
Gross Profit: | HKD5.72B (71.25 %) |
EPS: | HKD0.280 |
Financial Reports:
No articles found.
CSPC Pharmaceutical Group Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.100 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.110 (N/A) |
HKD0.140 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0365 | 2003-08-28 |
Last Dividend | HKD0.140 | 2023-09-07 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 21 | -- |
Total Paid Out | HKD1.673 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.36 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.09 | |
Div. Directional Score | 8.84 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6969.HK | Ex Dividend Junior | 2023-09-06 | Semi-Annually | 0 | 0.00% | |
1988.HK | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
1066.HK | Ex Dividend Knight | 2023-10-19 | Semi-Annually | 0 | 0.00% | |
0144.HK | Ex Dividend Knight | 2023-09-26 | Semi-Annually | 0 | 0.00% | |
3613.HK | Ex Dividend Knight | 2023-05-10 | Annually | 0 | 0.00% | |
1612.HK | Ex Dividend Knight | 2023-09-05 | Annually | 0 | 0.00% | |
0669.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
9982.HK | Ex Dividend Knight | 2023-12-12 | Semi-Annually | 0 | 0.00% | |
2193.HK | Ex Dividend Junior | 2023-09-06 | Sporadic | 0 | 0.00% | |
1199.HK | Ex Dividend Knight | 2023-09-11 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.189 | 1.500 | 6.23 | 9.34 | [0 - 0.5] |
returnOnAssetsTTM | 0.150 | 1.200 | 5.01 | 6.01 | [0 - 0.3] |
returnOnEquityTTM | 0.224 | 1.500 | 8.62 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.325 | -1.000 | 6.75 | -6.75 | [0 - 1] |
currentRatioTTM | 2.63 | 0.800 | 1.867 | 1.494 | [1 - 3] |
quickRatioTTM | 2.27 | 0.800 | 1.336 | 1.069 | [0.8 - 2.5] |
cashRatioTTM | 1.180 | 1.500 | 4.56 | 6.83 | [0.2 - 2] |
debtRatioTTM | 0.0130 | -1.500 | 9.78 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 281.89 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.430 | 2.00 | 9.86 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.175 | 2.00 | 9.91 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0181 | -1.500 | 9.93 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.707 | 1.000 | 1.551 | 1.551 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.232 | 1.000 | 7.37 | 7.37 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 7.76 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.794 | 0.800 | 8.04 | 6.43 | [0.5 - 2] |
Total Score | 11.58 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 10.17 | 1.000 | 9.07 | 0 | [1 - 100] |
returnOnEquityTTM | 0.224 | 2.50 | 9.11 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.175 | 2.00 | 9.94 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.83 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.430 | 2.00 | 9.86 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.325 | 1.500 | 6.75 | -6.75 | [0 - 1] |
pegRatioTTM | -0.249 | 1.500 | -4.99 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.127 | 1.000 | 9.34 | 0 | [0.1 - 0.5] |
Total Score | 6.09 |
CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators